Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
TBD Cabozantinib Withdrawn
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn
Admelog Insulin lispro Cancelled
Beleodaq Belinostat Withdrawn
Blincyto Blinatumomab Withdrawn
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn
Xeljanz tofacitinib Cancelled
Erbitux Cetuximab Cancelled